A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany

Key facts

Sponsor

Pfizer

Principal Investigator

Pfizer CT.gov Call Center

Pfizer

Intervention

tafamidis 61mg (based on prescription data)(other)

Enrollment

1 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2026

Study locations (1)

• Pfizer, Berlin, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07560306
  [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy
  Brigham and Women's Hospital
• RECRUITINGPHASE2NCT07285044
  The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
  Mayo Clinic
• RECRUITINGNCT07218705
  A Study Of MCG In Cardiac Amyloidosis
  Mayo Clinic
• ENROLLING BY INVITATIONPHASE2NCT06723015
  Tau PET Outcomes With Anti-amyloid Immunotherapies
  Mayo Clinic
• RECRUITINGNCT07213297
  Comprehensive Program for Hereditary Transthyretin Amyloidosis
  Hospital de Alta Complejidad en Red
• RECRUITINGPHASE1NCT06790394
  Test-retest Study With [18F]FBB in Cardiac Amyloidosis
  Life Molecular Imaging GmbH
• RECRUITINGNANCT07112066
  Multimodality Cardiac Imaging for Disease Progression in ATTR-CM
  Dominik Benz
• RECRUITINGPHASE3NCT07207811
  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  Novo Nordisk A/S

See all trials for Amyloidosis →